Neurology Search
Neurology Neurology
narcolepsy
NARCOLEPSY

Narcolepsy is a chronic neurologic sleep disorder wherein the patient have excessive daytime sleepiness and rapid eye movement sleep is dysregulated.

It affects 1 in 1000 individuals, with prevalence of about 0.04% of general population.
The exact cause remains unclear.
Studies suggest a combination of genetic predisposition, abnormal neurotransmitter functioning and abnormal immune modulation.
Symptoms include excessive daytime sleepiness, cataplexy, sleep paralysis, sleep-related hallucinations, automatic behavior, fragmented nocturnal sleep and insomnia.

Narcolepsy Drug Information

Drug Information

Indication: Attention deficit hyperactivity disorder (ADHD).

Indication: Depression including depression w/ associated anxiety. Generalized anxiety disorder (GAD) including long-term ...

Indication: Depressive illness, symptoms of depressive disorder & obsessive compulsive disorder (OCD).

Indication: Depression, obsessive-compulsive disorder, premenstrual dysphoric disorder (PMDD).

Indication: Symptomatic treatment of depression w/ or w/o anxiety. Obsessive compulsive disorder, pre-menstrual dysphoric ...

Indication: ADHD, narcolepsy.

Indication: ADHD.

Indication: Depression. Bulimia nervosa.

Indication: Major depressive disorder, panic disorder w/ or w/o agoraphobia, premenstrual dysphoric disorder, social anxie...

Indication: ADHD in childn ≥6 yr, adolescents & adults.

1  /  3
1  /  3
Editor's Recommendations
Most Read Articles
Ivermectin improves survival in COVID-19 patients with severe pulmonary involvement
2 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Mental health problems spell trouble for diabetics
Yesterday
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Slight amino acid tweak weakens HBV
Tristan Manalac, 5 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).